There was no increased risk of infections with IV iron .
Gastrointestinal AEs were reduced with IV iron .
CONCLUSION Intravenous iron therapy is not associated with an increased risk of SAEs or infections .
Infusion reactions are more pronounced with IV iron
OBJECTIVE To amass all available evidence regarding the safety of intravenous ( IV ) iron preparations to provide a true balance of efficacy and safety .
Total infusion of low molecular weight iron-dextran for treating postpartum anemia.
AIM 135 puerperal women with iron deficiency anemia participated in our prospect i ve r and omized controlled trial in order to investigate alternative treatments to blood transfusion for anemia . MATERIAL S AND METHODS The criteria for the diagnosis of anemia were Hb < 8 g/dl and ferritine < 10 microg/dl . Women were r and omly separated in two groups , A and B. Women of group A ( n = 109 women ) received a total amount of 1000 mg low molecular weight ( LMW ) iron-dextran intravenously in two doses . Group B ( n = 26 ) was the control group . They received orally 800 mg daily for 30 days of iron protein-succinylate . Three weeks later women of both groups underwent a full blood count analysis . RESULTS Hemoglobin and ferritin levels increased significantly in group A compared to group B ( p < 0.0001 ) . No adverse side-effects due to the treatment were noted in either group . CONCLUSION It seems that total iron-dextran infusion is a safe and rapid therapy of iron-deficiency postpartum anemia increases the Hb level more rapidly than oral ferrous sulfate , and it also appears to replenish iron stores more rapidly
There was no increased risk of infections with IV iron .
Gastrointestinal AEs were reduced with IV iron .
CONCLUSION Intravenous iron therapy is not associated with an increased risk of SAEs or infections .
Infusion reactions are more pronounced with IV iron
OBJECTIVE To amass all available evidence regarding the safety of intravenous ( IV ) iron preparations to provide a true balance of efficacy and safety .